Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Significant Drop in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Free Report) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 27,400 shares, a decline of 13.0% from the September 30th total of 31,500 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily volume of 51,600 shares, the short-interest ratio is presently 0.5 days.

Avenue Therapeutics Price Performance

Avenue Therapeutics stock opened at $2.45 on Wednesday. The business has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $3.50. Avenue Therapeutics has a 12 month low of $1.70 and a 12 month high of $29.25. The stock has a market capitalization of $3.51 million, a PE ratio of -0.31 and a beta of -0.17.

Avenue Therapeutics (NASDAQ:ATXIGet Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($6.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.38).

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC bought a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXIFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned approximately 1.17% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

(Get Free Report)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

Featured Articles

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.